Teva Pharma (TEVA) to Acquire Auspex Pharma (ASPX) in $3.2B Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Teva Reinforces Leadership Position in CNS with Acquisition of Auspex
March 30, 2015 7:00 AM EDTExpected to strengthen Teva's core CNS franchise, establish Tevas leadership in underserved movement disorders space, provide compelling new treatment options for patients in need, and enhance Tevas long-term revenue and earnings growth
All-Cash Transaction with Enterprise Value of $3.2 Billion
JERUSALEM & LA JOLLA, Calif.--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Auspex Pharmaceuticals, Inc. (Nasdaq: ASPX), today announced that they have entered into a definitive merger agreement under which Teva will commence a tender offer for... More
